Synexus Further Strengthens Its Presence in Poland with the Acquisition of Osteomed

Synexus Further Strengthens Its Presence in Poland with the Acquisition of Osteomed

MANCHESTER, UK, May 02, 2012 (BUSINESS WIRE) -- Synexus has further strengthened its leadership position in Poland with the acquisition of Osteomed, for an undisclosed sum. Based in Warsaw, Medical Centre Osteomed is a well established and highly respected clinical research company, FDA audited, whose client list includes many of the world's leading pharmaceutical companies and CROs.

Lyceum Capital backed Synexus, a global leader in the recruitment and running of late phase clinical trials, will consolidate its presence in Warsaw into a new research clinic which is four times the size of Synexus' current Warsaw facility. In the past two years, Synexus will have quadrupled its capacity across its four sites in Wroclaw, Gdynia, Warsaw and Katowice.

Poland has become a significant player in the global clinical trials market with analysts predicting that it will grow to reach US$323m by 2015, offering attractive benefits including access to high quality medical expertise, significant cost advantages, a motivated patient population and excellent trial data quality.

Dr Christophe Berthoux CEO of Synexus said: "Synexus has long recognised the importance of Poland in the global clinical trials market in terms of the significant opportunities this region can offer. We have had a well-established presence in Poland for a number of years but felt that now was the time to further strengthen this, both in recognition of the area as well as in support of our business growth. The acquisition of Osteomed will enhance our capacity, brings us scientific expertise and experience in the field of bone diseases and access to an extensive patient database.

"It also creates a third pillar in our global infrastructure. We have 24 sites across the world and a significant presence in the UK, Germany and now Poland. Synexus' success in Poland will be used as a platform to grow our business across Central and Eastern Europe where we already have clinics in Hungary, Ukraine and Bulgaria. This infrastructure enables us to offer scale and capacity to clients as well as stability which are seen as vital by the pharmaceutical industry."

Dr Andrzej Sawicki and Piotr Sawicki, the owners of Osteomed, will remain with Synexus. Dr Sawicki, a recognised expert in clinical research in bone diseases, enhances the senior medical team. Piotr Sawicki is being appointed to a senior position within Synexus Poland.

Dr Andrzej Sawicki said: "Since I founded Osteomed eighteen years ago we have developed a solid reputation, which is a measure of our knowledge and experience as well as the high quality of our work. Synexus has a high regard for quality and professionalism and, therefore, we are very pleased to be working with them."

Dr Radoslaw Janiak, Managing Director of Synexus Central and Eastern Europe, who is responsible for management of the Polish sites, commented: "We are delighted to welcome Dr Sawicki and his experienced team to Synexus. Their clinical expertise is a great addition to Synexus and will enhance our standing as a world leader in clinical research."

This acquisition is a reflection of Synexus' continued success and its rapidly growing order book and reputation for delivery. Osteomed brings a pipeline of studies to Synexus as well as long established relationships with many of the leading pharma companies.

SOURCE: Synexus 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

PRA Health has hired a former FDA clinical research lead to help run its decentralized study unit.